| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
CX-157 manufacturers
- CX-157
-
- $176.00
-
2026-08-30
- CAS:205187-53-7
- Purity: 99.35%
- Supply Ability: 10g
|
| Product Name: | CX-157 | | Synonyms: | CX-157;Phenoxathiin, 3-fluoro-7-(2,2,2-trifluoroethoxy)-, 10,10-dioxide;CX 157,CX157;3-Fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide | | CAS: | 205187-53-7 | | MF: | C14H8F4O4S | | MW: | 348.27 | | EINECS: | | | Product Categories: | | | Mol File: | 205187-53-7.mol |  |
| | CX-157 Chemical Properties |
| Boiling point | 430.0±45.0 °C(Predicted) | | density | 1.549±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | CX-157 Usage And Synthesis |
| Uses | CX-157 is a reversible inhibitor of monoamine oxidase-A (MAO-A) with an EC50 of 19.3 ng/mL. | | in vivo | CX-157 is a reversible inhibitor of monoamine oxidase-A (MAO-A) with an EC50 of 19.3 ng/mL. CX-157 is an investigational compound currently in development for the treatment of major depressive disorder (MDD). Mechanistic studies in animals have shown that CX-157 acts to inhibit MAO-A activity in a reversible and competitive manner, elevating brain levels of monoamine neurotransmitters[1]. | | References | [1] Fowler JS, et al. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31. DOI:10.1038/npp.2009.167 |
| | CX-157 Preparation Products And Raw materials |
|